Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk (scientific article published on 05 June 2006)

Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives

Q68071251

Oral contraceptives and endometrial cancer: do other risk factors modify the association?

Q70694780

Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study

Q71126153

Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA)

Q72130727

Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta

Q73403879

Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40

Q73645480

Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?

Q77415599

P433

issue

P921

main subject

estrogen

Q277954

endometrial cancer

Q944777

P304

page(s)

535-540

P577

publication date

2006-06-05

P1433

published in

Gynecologic Oncology

Q5625182

P1476

title

Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk

P478

volume

103

Reverse relations

cites work (P2860)

Q94221905	Association of Combined Estrogen–Progestogen and Progestogen-Only Contraceptives with the Development of Cancer
Q36905719	Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer
Q53701146	Could ALDH2*2 be the reason for low incidence and mortality of ovarian cancer for East Asia women?
Q34195371	DNA methylation in endometrial cancer
Q30049057	Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies
Q36914151	Endometrial evaluation with transvaginal ultrasonography for the screening of endometrial hyperplasia or cancer in premenopausal and perimenopausal women
Q60728526	Exogenous Hormone Use and Endometrial Cancer in U.S. Black Women
Q64767179	Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions
Q37293672	Molecular pathogenesis of endometrial and ovarian cancer
Q90317700	Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions
Q34132130	Oral contraceptive use among women in the military and the general U.S. population
Q80356892	Ovarian cancer and HRT in the Million Women Study
Q37718405	Progesterone potentiates the growth inhibitory effects of calcitriol in endometrial cancer via suppression of CYP24A1.
Q51743129	Recognizing Gynecological Cancer in Primary Care: Risk Factors, Red Flags, and Referrals.
Q35676052	The epidemiology of endometrial and ovarian cancer
Q34690392	Understanding obesity and endometrial cancer risk: opportunities for prevention
Q34930051	Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006.

P356	DOI	10.1016/J.YGYNO.2006.03.046
P698	PubMed publication ID	16740300